Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

35.54 -0.43 (-1.20%)
Streaming Delayed Price Updated: 3:46 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Veracyte Announces Second Quarter 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
Veracyte's Earnings: A Preview
Veracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Veracyte will... 
Via Benzinga
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
From Veracyte, Inc.
Via Business Wire
Small Cap Biotech Stocks Are Trending Well
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows. 
Via Benzinga
Analyst Ratings for Veracyte
Within the last quarter, Veracyte (NASDAQ:VCYT) has observed the following analyst ratings: 
Via Benzinga
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. 
Via Benzinga
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
From Veracyte, Inc.
Via Business Wire
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
From Veracyte, Inc.
Via Business Wire
Small Cap Biotechs Regain Momentum
Smaller cap biotech stocks soared off from recent lows looking like a redux of early 2021 when prices were double that of current values. 
Via Talk Markets
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
From Veracyte, Inc.
Via Business Wire
Bear Market Rally Lifts HealthCare Stocks Off Bottom
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma. 
Via Talk Markets
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
From Veracyte, Inc.
Via Business Wire
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
From Veracyte, Inc.
Via Business Wire
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
From Veracyte, Inc.
Via Business Wire
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
From Veracyte, Inc.
Via Business Wire
Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
From Veracyte, Inc.
Via Business Wire
Veracyte Earnings Perspective: Return On Capital Employed
Veracyte (NASDAQ:VCYT) brought in sales totaling $67.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 37.36%, resulting in a loss of $14.46 million. 
Via Benzinga
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
From Veracyte
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 351 stocks hit new 52-week lows. 
Via Benzinga
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
From Veracyte, Inc.
Via Business Wire
Recap: Veracyte Q1 Earnings
Veracyte (NASDAQ:VCYT) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by... 
Via Benzinga
Veracyte Announces First Quarter 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter. 
Via Benzinga
Preview: Veracyte's Earnings
Veracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Veracyte will... 
Via Benzinga
Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
From Veracyte, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.